CRISPR Therapeutics Faces Stock Challenges Despite Analyst Optimism
CRISPR Therapeutics has been experiencing a challenging period in the stock market, with its shares trading at $59.03, which is approximately 48% below the average Wall Street price target of $87.56. Despite the company's ownership of the only approved gene therapy of its kind, the stock has not reflected the optimism of analysts who foresee significant potential gains. One analyst from Piper Sandler has set a target of $110, suggesting an upside of around 86% from current levels.
The company co-developed CASGEVY with Vertex Pharmaceuticals, marking the first CRISPR-based gene therapy approved for commercial use. This therapy addresses sickle cell disease and transfusion-dependent beta thalassemia and has been approved in 39 countries. In the second quarter, partner-reported revenue for CASGEVY surged by 151% year-over-year, reaching $76 million. However, this commercial success has not translated into stock performance, as CRISPR's shares have declined by nearly 5% over the past year, while the S&P 500 has risen by almost 16%.
For Your Trading Desk
Sponsor Spike Success.
Financial reports indicate a significant drop in revenue, with a full-year 2025 revenue projection of only $3.51 million and a staggering 97.5% year-over-year decline in Q4 2025 revenue to $864,000. This decline was attributed to the expiration of a cost-deferral arrangement with Vertex and increased collaboration expenses. The first quarter of 2026 also saw revenue miss expectations by over 65%. The company's cash burn has been substantial, with a reported net loss of $581.6 million for 2025.
Despite these challenges, Edward Tenthoff from Piper Sandler remains optimistic, having raised his target to $110 after CRISPR closed a $600 million convertible note offering, which bolstered its cash reserves to approximately $2.56 billion. This financial cushion is expected to support research and development efforts without the need for dilutive equity raises. Tenthoff anticipates that CASGEVY could generate around $300 million in revenue in 2026, particularly if the FDA grants clearance for pediatric use, which would expand the patient base.
Analysts Diverge on Revenue Projections
In contrast, the consensus among analysts is much more conservative, with the average revenue estimate for 2026 sitting at just $40.83 million, increasing to $156.58 million in 2027. Any acceleration in the adoption of CASGEVY could lead to significant upward revisions in these estimates.
The company's wholly-owned pipeline presents additional opportunities, with upcoming data from CTX310's Phase 1b trial and results from zugo-cel for autoimmune and B-cell lymphoma treatments expected soon. Recent upward revisions in earnings per share also indicate a positive shift, with 12 upward revisions compared to three downward revisions in the past month.
Market Dynamics and Future Outlook
CRISPR Therapeutics is currently trading at a market cap of $5.71 billion, with shares up 13.89% over the past week and 12.57% year-to-date. However, the stock remains down 4.94% over the last year. The broader market context shows that while CRISPR has an approved product generating revenue, it still faces significant challenges in gaining investor confidence amid a volatile biotech landscape. Investors are weighing the potential for CASGEVY's commercial ramp against the backdrop of cash burn and uncertain pipeline outcomes.
The outlook for CRISPR Therapeutics hinges on the successful commercialization of CASGEVY and the performance of its pipeline products. Analysts are cautiously optimistic, but the stock's performance will depend on the company's ability to navigate its financial challenges and deliver on revenue expectations. As the market continues to evolve, CRISPR's position as a leader in gene therapy could either solidify or weaken, depending on upcoming clinical data and market reception.




